Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Biomolecules. 2023 Aug 1;13(8):1208. doi: 10.3390/biom13081208.
Chronic hepatitis B virus (HBV) infection leads to the development of cirrhosis and hepatocellular carcinoma. Lifelong treatment with nucleotides/nucleoside antiviral agents is effective at suppressing HBV replication, however, adherence to daily therapy can be challenging. This review discusses recent advances in the development of long-acting formulations for HBV treatment and prevention, which could potentially improve adherence. Promising new compounds that target distinct steps of the virus life cycle are summarized. In addition to treatments that suppress viral replication, curative strategies are focused on the elimination of covalently closed circular DNA and the inactivation of the integrated viral DNA from infected hepatocytes. We highlight promising long-acting antivirals and genome editing strategies for the elimination or deactivation of persistent viral DNA products in development.
慢性乙型肝炎病毒(HBV)感染可导致肝硬化和肝细胞癌的发生。长期使用核苷酸/核苷抗病毒药物治疗可有效抑制 HBV 复制,但每日坚持治疗可能具有挑战性。本综述讨论了用于 HBV 治疗和预防的长效制剂的最新进展,这些进展可能会提高治疗的依从性。总结了针对病毒生命周期不同步骤的有前途的新型化合物。除了抑制病毒复制的治疗方法外,治愈策略还集中在消除共价闭合环状 DNA 和失活感染肝细胞中的整合病毒 DNA 上。我们重点介绍了有前途的长效抗病毒药物和基因组编辑策略,用于消除或失活开发中的持续病毒 DNA 产物。